Kiora Pharmaceuticals
KPRX----
Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Kiora Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jun 22, 2026Price forecast
$12.00370.59%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · Jul 16 at 09:31 AM
10:31 ETComplement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight
- StockTitan · Jul 1 at 10:00 PM
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | KPRX Stock News
- StockTitan · Jun 17 at 10:00 PM
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | KPRX Stock News
- TradingView · May 8 at 06:11 AM
Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary
- Earnings Watch · May 8 at 06:09 AM
Kiora Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0
- Earnings Watch · May 8 at 06:08 AM
Kiora Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0
